A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine

Completed · Phase 1 · Has a placebo group

Conditions studied: Migraine

In brief

The main goal of this trial is to learn more about the safety and tolerability of Lu AG09222 when taken together with ubrogepant. This includes looking for any new or worsening medical issues the participants have with the treatment. During the trial, participants with migraine will receive ubrogepant oral tablets and an injection of either Lu AG09222 or a placebo.

Key facts

Study ID
NCT06578585
Run by
H. Lundbeck A/S
People needed
43
Starts
2024-09-13
Expected to finish
2025-07-11
Last updated by the study team
2025-10-14

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.